Error 404!
Something went wrong
It seems like we've stumbled upon uncharted territory. The path you followed may have led to a dead end, or the page you were seeking has ventured into the great unknown. But fear not, we're here to help you get back on track.
Latest Articles
Market Trends
Meta Capex Discipline vs Micron Memory Boom: Why the Market Cap Crossover Matters
Meta is the signal and Micron is the noise | investingLive
Micron briefly surpassed Meta in market capitalization, and that crossover...
Market Trends
Consumer spending rises as cheaper gas promises relief
Consumer spending rises again - and now cheaper gas is on the way
U.S. consumers kept the economy humming in May as spending grew faster...
Economy
2026 Toyota Hilux first drive: smarter, tougher and far more refined in Namibia
FIRST DRIVE | Testing the 2026 Toyota Hilux through Namibia
Namibia can feel uncannily familiar to South Africans: wide horizons, flat scrubland, and crisp, well-marked...
Economy
How Solar Power Is Cutting Costs and Boosting Growth for Nigerian Businesses
Businesses turn to solar to cut energy costs
Across Nigeria, more businesses are turning to solar energy to cut operating costs, stay productive during grid...
Startups
Labor tax reforms explained: CGT, negative gearing and SMSF borrowing changes
Everything you need to know about Labor's latest tax changes
After a last‑minute agreement with the Greens, Parliament has passed wide‑ranging tax reforms that reshape...
Startups
How a Bootstrapped Wellness Brand Is Rethinking India’s Supplements Market
Bootstrapped at 50: How Purezen Is Quietly Rewriting India's Wellness Playbook | Startup Story
Most people spend their fifties winding down. Mitesh Desai spent his...
Startups
Cred Raises $900 Million as Founder Moves to WhatsApp: What Happens Next for the Fintech Startup
Cred Gets $900 Mn and Loses Its Founder: What Comes Next for the Fintech Startup
Cred has entered a pivotal new phase: the fintech platform...
Startups
AbbVie Deepens Immunology Push With $11B Apogee Deal and Long-Dosing Eczema Therapy
AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge
AbbVie is expanding its immunology leadership with a deal to acquire Apogee Therapeutics for...